



**Control Report for the
Annual Report for**

Novo Nordisk Pharma Operations A/S

32657222

Contents

Guide for use of control report

Digital financial statements in pdf and XBRL format

The annual report must be filed with the Danish Business Authority in two versions: a readable pdf version (may be a system generated pdf file or a scanned version of the signed annual report) and an XBRL file containing raw data in XBRL format. It requires a special program to be able to present data in the XBRL file.

The financial statements in the pdf file must reflect the true and fair view. In the nature of the case, the XBRL file has no visual appearance, but the raw data must correspond to the figures and the text from the annual report.

The purpose of the control report

The control report is used solely to verify the information in the XBRL file and is one way of presenting the annual report. Thus, the control report is a reproduction of the XBRL file in a readable format. The purpose of the control report is solely to form a basis for control of the marking off of data, and therefore the visual expression of the control report is not important.

In the control report, you must decide:

1. Whether figures and text in grey areas are identical with the signed annual report.
2. Whether figures and text have been marked off to specific fields in the taxonomy.

In the control report, the headings over the grey areas refer to the field in the taxonomy to which the grey text is marked off. If there is also a heading inside grey area, this is just a repetition from the actual annual report and is not a double heading.

Revisor:	Nettoomsætning	
Revisors:	Nettoomsætning	the
Vores ansvar er at udtrykke en ki		

In the income statement, balance sheet and cash flow statement, the top line states the field in the taxonomy to which the figures are marked off, whereas the line in italics immediately below states the name of the line in the annual report.

At accounting line level, it is important to check that the field in the taxonomy to which an accounting line is marked off corresponds to the accounting line in the signed annual report. The text may differ, but the meaning must be the same. Thus, it is permitted to mark off "rental income" to "revenue" as the taxonomy does not include the field rental income. The accounting lines may also be reported at a higher level in the taxonomy if no appropriate line is available.

In the control report, you should **not** decide on:

- Note numbers and references as well as the order
- Layout and formatting
- The order of the part elements of the annual report
- Line breaks
- Appearance of notes and texts

Submission information

Report

Information on type of submitted report Årsrapport

Entity

Identification number [CVR] 32657222
Name Novo Nordisk Pharma Operations A/S
Date of foundation 2009-12-18
Registered office Gladsaxe
Address , street name Novo Allé, c/o Novo Nordisk A/S
Address , post code identifier 2880
Address , district name Bagsværd
Address , country Denmark

Auditor

First name and surname Torben Jensen
Identification number [CVR] of audit firm 33771231
Name of audit firm PricewaterhouseCoopers Statsautoriseret
Revisionspartnerselskab
Description State Authorised Public Accountant
Address , street name Strandvejen
Address , street building identifier 44
Address , post code identifier 2900
Address , district name Hellerup

Executive board

First name and surname of member (1) Claus Sølje

Supervisory board

First name and surname of member (1) Ole F. Ramsby
Title of member (1) Chairman
First name and surname of member (2) Karsten Munk Knudsen
First name and surname of member (3) Anne Mette Vogelsang

Information on enterprise submitting report

Identification number [CVR] of submitting enterprise 32657222
Name of submitting enterprise Novo Nordisk Pharma Operations A/S
Address of submitting enterprise, street and number Novo Allé 1
Address of submitting enterprise, post code and district name 2880 Bagsværd

Other informations

Reporting period start date 2016-01-01
Reporting period end date 2016-12-31

Date of general meeting	2017-04-25
First name and surname of chairman of general meeting or person, who acts as chairman	Emilie Rast
Class of reporting entity	Regnskabsklasse B
Type of auditor assistance	Revisionspåtegning
Reporting period start date last year	2015-01-01
Reporting period end date last year	2015-12-31
Currency:	DKK

Statement by the Board of Directors and Executive Management

Statement by management

Statement by the Board of Directors and Executive Management

Identification of approved annual report

Today, the Board of Directors and Executive Management have approved the Annual Report of Novo Nordisk Pharma Operations A/S for the financial year 1 January – 31 December 2016.

Confirmation that annual report is presented in accordance with requirements provided for by legislation, any standards and requirements provided by articles of association or by agreement

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

Confirmation that financial statements gives true and fair view of assets, liabilities, equity, financial position and results

In our opinion, the Financial Statements give a true and fair view of the financial position at 31 December 2016 of the Company and of the results of the company's operations for 2016 in accordance with the Danish Financial Statements Act.

Recommendation of annual report for approval by general meeting

We recommend that the Annual Report be adopted at the Annual General Meeting.

Date of approval of annual report

2017-04-25

Place of signature of statement by management

Bagsværd

Executive board

Claus Sølje

Supervisory board

Ole F. Ramsby
Chairman

Karsten Munk Knudsen

Anne Mette Vogelsang

Auditor's reports

The independent auditor's reports (Audit)

Independent Auditor's report

Addressee of auditor's report on audited financial statements

To the Shareholder of Novo Nordisk Pharma Operations A/S

Opinion on audited financial statements (audit)

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2016, and of the results of the Company's operations for the financial year 1 January - 31 December 2016 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Novo Nordisk Pharma Operations A/S for the financial year 1 January - 31 December 2016, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.

Basis for conclusion (Audit)

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on management's review [Auditor's report on audited financial statements]

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the Financial Statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information

required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Statement of executive and supervisory board's responsibility for financial statements (Audit)

Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Statement of auditor's responsibility for the audit of the financial statements (Audit)

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the Financial Statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence

obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and contents of the Financial Statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Signature of auditor, place

Bagsværd

Signature of auditor, date

2017-04-25

First name and surname of auditor

Torben Jensen

Description of auditor

State Authorised Public Accountant

Name of audit firm

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab

Identification number [CVR] of audit firm

33771231

Management Review

Management's review

Management Review

Main activities

The purpose of the company is to establish and own branches and shares in domestic and foreign companies, to make investments and financial dealings, including domestic and foreign placement of capital in companies and real estate, and at the discretion of the board of directors to support the operations of such companies. The Company aims also to support the Novo Nordisk A/S pharmaceutical activities.

Trends during the financial year

The net profit for Novo Nordisk Pharma Operations A/S ended at DKK 2,324 thousand for the year 2016 compared to DKK 1,377 thousand for the year 2015.

Events after the balance sheet date

No events have occurred after the end of the reporting period which materially affect the financial standing of the company.

Foreign branches

The company has branches in Kosovo, Montenegro, Vietnam, Iraq, Peru, Saudi Arabia and Colombia (under liquidation).

Accounting policies

Information on reporting class of entity

The Annual Report of the Company is prepared in accordance with the Danish Financial Statements Act for a class B enterprise.

Class of reporting entity

Regnskabsklasse B

Description of general matters related to recognition, measurement and changes in accounting policies

The Annual Report is presented in DKK 1,000.

Description of methods of recognition and measurement basis of property, plant and equipment

Property, plant and equipment

Property, plant and equipment are measured at cost less accumulated depreciation and less any accumulated impairment loss. Depreciation is provided under the straight-line method over the estimated useful lives of the assets

Other fixtures and fittings 3-16 years

Assets with a short estimated useful life is recognised in the income statement at the date of acquisition.

If the carrying amount of property, plant and equipment are higher than the recoverable amount, the asset is written down to its lower recoverable amount.

Description of methods of recognition and measurement basis of receivables

Amounts owed by affiliated companies

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable.

Description of methods of recognition and measurement basis of liabilities other than provisions

Long and short term debt

Long and short term debts are measured at amortised cost.

Description of methods of recognition and measurement basis for dividends

Dividend

Proposed dividends (not yet declared) for the accounting period are recognised in retained earnings.

Description of methods of recognition and measurement basis of revenue

Income recognition

Revenues are recognised as earned.

Description of methods of recognition and measurement basis of finance income and expenses

Financial items

Financial income and expenses include interest income and expenses, realised and unrealised gains and losses on debt and transactions denominated in foreign currencies and amortisation of financial assets and liabilities. Financial income and expenses are recognised at the amounts that concern the reporting period.

Description of methods of recognition and measurement basis of tax expense

Income taxes

Income tax in the income statement comprises current tax for the year and any change in the provision for deferred tax.

Novo Nordisk recognises deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences can be utilised.

Tax payable/receivable includes tax payable computed on the basis of the expected taxable income for the year and any adjustments of taxes payable for previous years.

The company is jointly taxed with the Danish companies in the Novo A/S Group. The tax effect of the joint taxation with the parent company and other subsidiaries is allocated to the companies in proportion to their taxable incomes (full allocation). The current tax in the joint taxation is paid by the ultimate parent company, Novo A/S, which functions as the tax administration company. The jointly taxed Danish enterprises have adopted the on-account taxation scheme.

Description of methods of translation of foreign currencies

Translation of foreign currencies

Foreign currency transactions are translated into DKK using the exchange rates prevailing at the transaction dates. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Income statement.

Income Statement 1. January 2016 - 31. December 2016

	Note	01-01-2016 31-12-2016 x1000 DKK	01-01-2015 31-12-2015 x1000 DKK
Revenue		81.489	85.104
<i>Income from service activity</i>			
Administrative expenses	1	-13.428	-9.541
<i>Administrative costs</i>			
Other operating expenses	1	-65.551	-71.015
<i>Expenses from service activity</i>			
Profit (loss) from ordinary operating activities		2.510	4.548
<i>Operating profit/(loss)</i>			
Other finance income	2	978	83
<i>Financial income</i>			
Other finance expenses	3	-813	-583
<i>Financial expenses</i>			
Profit (loss) from ordinary activities before tax		2.675	4.048
<i>Profit/(loss) before income taxes</i>			
Tax expense		-351	-2.671
<i>Income taxes (gain)/loss</i>			
Profit (loss)		2.324	1.377
<i>NET PROFIT/(LOSS) FOR THE YEAR</i>			
Proposed distribution of results			
		01-01-2016 31-12-2016 x1000 DKK	01-01-2015 31-12-2015 x1000 DKK
Profit (loss)			
Retained earnings		2.324	1.377
Profit (loss)		2.324	1.377
<i>NET PROFIT/(LOSS) FOR THE YEAR</i>			

Balance

Assets

	Note	31-12-2016 x1000 DKK	31-12-2015 x1000 DKK
Property, plant and equipment <i>Property, plant and equipment</i>	4	3.173	351
Non-current deferred tax assets <i>Deferred income tax</i>	5	594	411
Short-term receivables from group enterprises <i>Amounts owed by affiliated companies</i>		12.121	42.300
Other short-term receivables <i>Other receivables</i>		7.545	5.475
Cash and cash equivalents <i>Cash at bank and in hand</i>		19.816	6.958
Current assets <i>TOTAL CURRENT ASSETS</i>		39.482	54.733
Assets <i>TOTAL ASSETS</i>		43.249	55.495

Liabilities

	Note	31-12-2016 x1000 DKK	31-12-2015 x1000 DKK
Contributed capital <i>Share capital</i>	6	500	500
Retained earnings <i>Retained earnings</i>		8.416	6.092
Equity <i>TOTAL EQUITY</i>		8.916	6.592
Short-term trade payables <i>Trade payables</i>		456	336
Short-term payables to group enterprises <i>Amounts owed to affiliated companies</i>		14.648	13.133
Short-term tax payables <i>Tax payables</i>		72	1.626
Other short-term payables <i>Other liabilities</i>	7	19.157	33.808
Short-term liabilities other than provisions <i>TOTAL CURRENT LIABILITIES</i>		34.333	48.903
Liabilities other than provisions <i>TOTAL LIABILITIES</i>		34.333	48.903
Liabilities and equity <i>TOTAL EQUITY AND LIABILITIES</i>		43.249	55.495
Disclosure of contingent liabilities	8		
Information on related parties	9		
Disclosure of ownership	10		

Statement of changes in equity

Statement of changes in equity

Statement of changes in equity at 31 December

	Share capital DKK '000	Share premium DKK '000	Retained earnings DKK '000	Total DKK '000
2016				
Balance at the beginning of the year	500	0	6.092	6.592
Net profit/(loss) for the year			2.324	2.324
Balance at the end of the year	500	0	8.416	8.916
2015				
Balance at the beginning of the year	500	0	(285)	215
Paid in share capital		5.000		5.000
Transfer of share premium to retained earnings		(5.000)	5.000	0
Net profit/(loss) for the year			1.377	1.377
Balance at the end of the year	500	0	6.092	6.592

*) Paid in share capital amounts to nominal DKK 100 at a price of DKK 5,000,000.

Notes

Note 1

Disclosure of employee expense

Employee costs

	2016	2015
	DKK '000	DKK '000
Wages and salaries	44.157	34.612
Pensions	537	215
Other contributions to social security	2.334	1.710
Other employee costs	3.043	2.633
Total employee costs	50.071	39.170

According to the Danish Financial Statements Act §98b (3) executive management remuneration is not disclosed.

Average number of full-time employees at year-end	100	80
---	-----	----

Note 2

Disclosure of other finance income

Financial income

	2016	2015
	DKK '000	DKK '000
Foreign exchange gain (net)	957	80
Interest income	21	3
Total financial income	978	83

Note 3

Disclosure of other finance expenses

Financial expenses

	2016	2015
	DKK '000	DKK '000
Interest paid to affiliated companies	49	-
Interest paid	387	338

Other financial expenses	377	245
Total financial expenses	813	583

Note 4

Disclosure of property, plant and equipment

Property, plant and equipment	2016	2015
	DKK '000	DKK '000
Cost at the beginning of the year	1.680	1.290
Additions during the year	1.825	390
Cost at the end of the year	3.505	1.680
Depreciation and impairment losses at the beginning of the year	1.329	519
Depreciation for the year	997	810
Depreciation and impairment losses at the end of the year	332	1.329
Carrying amount at the end of the year	3.173	351

Note 5

Disclosure of deferred tax assets and liabilities

Deferred income tax assets/(liabilities)	2016	2015
	DKK '000	DKK '000
Net deferred tax asset/(liability) at 1 January	411	376
Income/(charge) to the Income statement	183	52
Income/(charge) to Equity	-	-17
Net deferred tax asset/(liability) at 31 December	594	411

Note 6

Disclosure of contributed capital

Share capital	2016	2015	2014	2013	2012
The share capital consists of 500,200 shares of nominal DKK 1.					

	DKK	DKK	DKK	DKK	DKK
Share capital 1 January	500.200	500.100	500.100	500.100	500.000
Capital contribution	-	100	-	-	100
Balance at the end of the year	500.200	500.200	500.100	500.100	500.100

Note 7

Disclosure of liabilities other than provisions

Other liabilities

	2016 DKK '000	2015 DKK '000
Duties payable	2.880	12.903
Employee costs payable	1.689	3.727
Other liabilities	14.588	17.178
Total other liabilities	19.157	33.808

Note 8

Disclosure of contingent liabilities

Contingent liabilities

The company is jointly taxed with the Danish companies in the Novo A/S Group. The joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to income taxes and withholding taxes may lead to a larger liability. The tax for the individual companies is allocated in full on the basis of the expected taxable income.

The Company has no other contingent liabilities.

Note 9

Information on related parties

Related parties and ownership

Controlling interests

Basis

Novo Nordisk Region International Operations A/S, Novo Allé, 2880 Bagsværd, Denmark	Principal shareholder, owns 100%
---	----------------------------------

Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark	Controls Novo Nordisk Region International Operations A/S
Novo A/S, Tuborg Havnevej 19, 2900 Hellerup, Denmark	Controls Novo Nordisk A/S
Novo Nordisk Fonden, Tuborg Havnevej 19, 2900 Hellerup, Denmark	Ultimate parent of the group

Note 10

Disclosure of ownership

Ownership.

The Company is a 100% owned subsidiary of Novo Nordisk Region International Operations A/S. The consolidated financial statements of Novo Nordisk A/S, which include the Company by full consolidation, can be obtained by contacting Novo Nordisk A/S (CVR. no. 24 25 67 90), Novo Allé, DK-2880 Bagsværd.

The ultimate parent company is Novo Nordisk Foundation. Consolidated financial statements can be obtained by contacting Novo Nordisk Fonden (CVR. no. 10 58 29 89), Tuborg Havnevej 19, 2900 Hellerup, Denmark.